Cisplatin is a platinum-based chemotherapy medicine used to treat many solid tumors including testicular, ovarian, cervical, bladder, head and neck, lung cancers, mesothelioma, brain tumors, and neuroblastoma. It is administered intravenously and is prescription-only. It is a foundational antineoplastic drug on essential medicines lists.
Neoadjuvant chemoimmunotherapy showed a 51.5% pathological complete response rate in 127 patients with resectable squamous cell lung cancer. Grade 3-4 treatment-related adverse events occurred in 11.8% of patients.
Ten-year follow-up of the phase 3 ESPATUE trial found similar overall and progression-free survival with chemoradiotherapy boost or surgery in resectable advanced NSCLC after induction therapy.
Moderna and Merck advance a Phase 2 trial of mRNA cancer vaccine V940 with pembrolizumab and chemotherapy for metastatic squamous NSCLC. In biliary tract cancer, first-line treatment combines chemotherapy with immunotherapy, while targeted therapy resistance prompts liquid biopsy. ImmunityBio tests a chemotherapy-free NK-cell regimen in non-Hodgkin lymphoma.
Junshi Biosciences reported total revenue of approximately RMB2,498 million in 2025, a 28% increase year-over-year, driven by toripalimab sales growth. Absci Corporation announced it will report fourth quarter and full year 2025 financial results on March 24, 2026.
Two recent clinical trials found that adding immunotherapy to standard chemoradiation did not improve survival for patients with limited-stage small-cell lung cancer or high-risk HPV-positive oropharyngeal cancer, though both studies revealed important insights about treatment delivery and radiation scheduling.
Researchers are developing personalized treatment approaches for rare and pediatric cancers using genetic profiling, AI-driven dosing, and 3D-printed medications to improve outcomes while reducing long-term toxicity.
Pembrolizumab-based regimens demonstrated significant survival improvements in two separate trials: KEYNOTE-B15 for muscle-invasive bladder cancer and KEYNOTE-B96 for platinum-resistant ovarian cancer, with FDA approval granted for the ovarian cancer indication.
Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.
Scientists at three institutions have developed distinct nanoparticle-based drug delivery systems designed to target cancer tumors more precisely while reducing side effects, with approaches ranging from DNA nanomachines to transformable nanofibers.
Phase III KEYNOTE-B15 trial demonstrates enfortumab vedotin plus pembrolizumab significantly improves event-free survival and pathologic complete response rates compared with cisplatin-based chemotherapy in muscle-invasive bladder cancer.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07598318 |
Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07583550 |
Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer |
NOT_YET_RECRUITING | PHASE2 |
| NCT07583511 |
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study |
RECRUITING | PHASE2 |
| NCT07579195 |
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07566156 |
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer ( EV-309 ) |
RECRUITING | PHASE3 |
| NCT07559929 |
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung CancerInhibitors or Platinum-Based Agents for Small Cell Lung Cancer. |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07554456 |
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07540390 |
GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. |
NOT_YET_RECRUITING | PHASE3 |
| NCT07531979 |
Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2 |
NOT_YET_RECRUITING | PHASE2 |
| NCT07528495 |
A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's |
RECRUITING | PHASE2/PHASE3 |
